Syndax Pharmaceuticals announced it can now advance on plans for its open-label Phase I/II study to assess its small molecule inhibitor candidate SNDX-5613 in patients with relapsed/refractory acute leukemia. The trial's primary endpoint is the rate of complete remission in three expansion cohorts.
Syndax study for leukemia candidate SNDX-5613 advances
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.